highgreennews

Latest posts

Medical cannabis patients in Germany set to top one million

A new report into the German cannabis market estimates the total number of patients has risen 60,000 in less than two years since first approved for medical use.

The ‘Germany Cannabis Report’ from Prohibition Partners also states that within a few years that number will have risen to one million patients. And, it estimates the total German cannabis market will be worth €16.2 billion by 2028, with the medicinal cannabis market estimated to be worth €7.7 billion by the same time.

This comes as Canadian firm Aphria, one of the few from that country to be currently showing a profit, says that by next year Germany will be contributing almost half its revenues. 

German Boost For Aphria

In a first quarter results announcement Aphria said with 2020 revenue projections estimated at $700 million, its ‘German distribution business will represent slightly more than half of the total net revenue’. 

Daragh Anglim, Managing Director Prohibition Partners, says in the introduction to the report, released in mid-October, that the rapid growth of the German market ‘is unprecedented in Europe’. 

Adding: “Major change has followed across the continent but Germany remains one of the most open, promising and exciting markets in the region.” 

The report highlights the supply problems facing the German market which is currently reliant on imports from Canada, Holland, Portugal and Australia. In an effort to combat this production licences were granted earlier this year, and of the 13 lots, Aphria and Aurora secured five, and Demecan received the remaining three lots. 

23 Euros Per Gram

Each lot allows the holder to grow 200 kilograms per year for a four-year period. And the report adds: “The reality is that the German tendered facilities are not going to meet the domestic medical cannabis quantity demand.” 

It says patients requesting medicinal cannabis are being supported by a robust public health insurance regime, which covers 90% of the population. The monthly allowance 100 gramme is generous and the ‘insurance companies cover all cannabis treatments and do not specify which conditions are covered’. 

Medicinal cannabis in Germany is very expensive, however, with an average price to patients of between €20 and €25 per gram for flower. In the Netherlands, medical cannabis is sold to patients for approximately €7 per gram, says the report.

CALIFORNIA | After Newsom bans pot use in limos, and for hospital patients, cannabis advocates are angry

SACRAMENTO — 

 

Gov. Gavin Newsom led the campaign to legalize marijuana in California three years ago but has since angered some in the industry by refusing to allow pot in hospitals and outlawing its use on tour buses and in limousines.

CANADA | Former task force chair sees warning signs from first year of decriminalized cannabis

The former lead of the federally appointed task force for the legalization of cannabis says the first year has gone "extremely well" but there are "yellow flags veering to red" on vaping as laws governing the next wave of pot products come into force.

Anne McLellan, the former deputy prime minister and head of the team of experts assembled by the Liberal government to make recommendations on how recreational pot should be legalized, said the growing number of vaping-related illnesses on both sides of the border is giving her pause.

For Young Farmers, Hemp Is a ‘Gateway Crop’

Asaud Frazier enrolled in Tuskegee University with plans to study medicine, but by the time graduation rolled around in 2016, he’d already switched gears. Instead of becoming a physician, Frazier decided to farm hemp.

“I was always interested in cannabis because it had so many different uses,” he said. “It’s a cash crop, so there’s no sense in growing anything else. Cannabis is about to totally take over an array of industries.”

Medical Marijuana May Help Lessen Opioid Use and Potential Abuse

Medical marijuana shows early promise to lessen opioid use and potential abuse, suggests a systematic review of published studies being presented at the ANESTHESIOLOGY® 2019 annual meeting. However, much more rigorous scientific research must be done to determine if there truly are pain relief benefits to medical marijuana that can ease chronic pain and outweigh potential risks.

Georgia’s new medical marijuana program stalls 6 months after law signed

Six months after Gov. Brian Kemp signed a law allowing companies to grow and sell medical marijuana in Georgia for the first time, the program remains stalled because he and other top politicians still haven’t appointed members of a commission to oversee the expansion. 

Aides to Kemp, Lt. Gov. Geoff Duncan and House Speaker David Ralston haven’t said why there’s no members yet for the Georgia Access to Medical Cannabis Commission. But until they do, the expansion is effectively sidelined. 

The legislation, House Bill 324, gave the seven-member commission vast oversight over the state’s medical marijuana operation, including picking which businesses can grow the plant and developing the licensing requirements that retailers must meet to sell it.

It’s a cornerstone of legislation that creates a new but limited marijuana industry in Georgia. The legislation was celebrated as a milestone for patients who were previously allowed to use the drug — but had to violate state and federal laws to purchase it.

One potential cause for the lag time is that the commission is essentially a startup, unlike other boards and agencies with built-in procedures and existing members. State officials say they’ve been inundated with applications — more than 50 candidates have surfaced for the spots.

The law also sets strict requirements for appointments, including a rule that commission members must not have any ownership stake or other financial interest in a cannabis oil firm during their term — and five years after it ends.

Still, the delay is a setback for patients and their families who celebrated the law’s passage with hopes it would provide much-needed treatment for severe seizures, terminal cancers, Parkinson’s disease and other illnesses. 

“It’s extremely frustrating for medically fragile patients to finally get a bill passed that allows the distribution of medical cannabis oil, and then still be waiting on Governor Kemp to establish the commission,” said Blaine Cloud, whose daughter Alaina suffers from a severe form of epilepsy that could be treated by the drug. 

“Registered patients and many others continue to suffer every day – and will continue to suffer since it will take time to get companies licensed once the commission is finally established.”

Georgia’s new medical marijuana program stalls 6 months after law signed

Six months after Gov. Brian Kemp signed a law allowing companies to grow and sell medical marijuana in Georgia for the first time, the program remains stalled because he and other top politicians still haven’t appointed members of a commission to oversee the expansion. 

Aides to Kemp, Lt. Gov. Geoff Duncan and House Speaker David Ralston haven’t said why there’s no members yet for the Georgia Access to Medical Cannabis Commission. But until they do, the expansion is effectively sidelined. 

The legislation, House Bill 324, gave the seven-member commission vast oversight over the state’s medical marijuana operation, including picking which businesses can grow the plant and developing the licensing requirements that retailers must meet to sell it.

It’s a cornerstone of legislation that creates a new but limited marijuana industry in Georgia. The legislation was celebrated as a milestone for patients who were previously allowed to use the drug — but had to violate state and federal laws to purchase it.

One potential cause for the lag time is that the commission is essentially a startup, unlike other boards and agencies with built-in procedures and existing members. State officials say they’ve been inundated with applications — more than 50 candidates have surfaced for the spots.

The law also sets strict requirements for appointments, including a rule that commission members must not have any ownership stake or other financial interest in a cannabis oil firm during their term — and five years after it ends.

Still, the delay is a setback for patients and their families who celebrated the law’s passage with hopes it would provide much-needed treatment for severe seizures, terminal cancers, Parkinson’s disease and other illnesses. 

“It’s extremely frustrating for medically fragile patients to finally get a bill passed that allows the distribution of medical cannabis oil, and then still be waiting on Governor Kemp to establish the commission,” said Blaine Cloud, whose daughter Alaina suffers from a severe form of epilepsy that could be treated by the drug. 

“Registered patients and many others continue to suffer every day – and will continue to suffer since it will take time to get companies licensed once the commission is finally established.”

Slow rollout in marijuana sales costs Maine revenue and jobs

From legalization to legal sales, Maine is inching toward the slowest adult-use marijuana rollout in the U.S., with economists saying the three-year wait for stores to open will have cost Maine more than $82 million in taxes and 6,100 industry jobs.

The delay has caused some investors and industry experts to take their dollars and skills to other states, consultants say. Many of those who remain behind, committed to Maine, are spending cash they haven’t got to be ready for a market launch that is two years longer than average.

David Carr and Ray Payne have spent at least $750,000 waiting for that green light. That is what it took to lock down and hold on to the properties and personnel they will need to apply for the licenses required to open a recreational grow, manufacturing lab and retail store in Portland.

Image removed.

Ray Payne, left, and David Carr of Coast 2 Coast Extracts stand in their empty cultivation warehouse in Portland. The partners have been making lease, insurance and security system payments on the space they hope to use to grow marijuana once the adult-use recreational industry is cleared to launch. Shawn Patrick Ouellette/Staff Photographer

And because this is cannabis, a federally illegal industry without access to traditional banking, Carr and Payne have had to turn to private investors, incurring high-interest debt and handing over equity in the company, to float the business until they can even hope to start making money.

“We are going deeper into debt every day,” Carr said. “We are pretty lucky. We have investors who really understand the cannabis space. They understand the risks, the delays. A lot of people don’t. But it’s debt we shouldn’t have, you know? We’ll be paying for this delay long after we open.”

Maine voted to legalize adult-use marijuana in November 2016. After legislative rewrites, gubernatorial vetoes, and contractual snafus, state regulators are now saying Maine will record its first adult-use sales on March 15, or 1,223 days after voters narrowly approved full-scale legalization at the polls.

The seven states that legalized recreational marijuana use and sales before or at the same time as Maine – Colorado, Washington, Alaska, Oregon, California, Massachusetts and Nevada – required an average of 497 days from legalization to record their first sales.

Even Michigan and Illinois, which legalized adult-use marijuana in 2018 and 2019, predict their markets will launch before Maine’s. Illinois adopted its legalization law last July and is predicting stores will open on Jan. 1, 2020, making its 160-day rollout the fastest in U.S. history.

AN ECONOMIC PLAYER

Maine’s recreational cannabis market will top $158 million in sales its first year and almost $252 million in its second, according to economist Beau Whitney at New Frontier Data, a national marijuana research company that has studied legal and illegal market development in other legalized states.

Image removed.

These growth estimates are based on state population, marijuana consumption, medical marijuana sales and tourism trends, as well as the similarity of Maine’s proposed regulatory model with other markets. It assumes the black market will continue to serve 25 percent of total demand.

Using a conservative multiplier, where $1 spent is worth $2 to the economy, Whitney projects the adult-use market would have pumped more than $800 million into the Maine economy if the state could have pulled off an average rollout of 497 days instead of its 1,223 crawl to its first sale.

Based on Whitney’s projections, which have proven accurate in other markets, and the state’s tax rate of 20 percent, Maine could have made $82 million in marijuana taxes over those two extra years. That does not include other state taxes that would be collected, like payroll or income taxes.

Based on its projected size, New Frontier estimates Maine’s adult-use market will create 3,967 jobs in its debut year and 6,288 jobs in its second. These are plant-touching jobs only, like growers, chemists and retail clerks. The figures don’t include new indirect jobs, like accountants, security or human resources.

The average wage in the cannabis industry is about $17.50 an hour, or $36,400 a year, but that includes management positions and highly technical jobs requiring advanced degrees, like chemists. Most jobs in cannabis are relatively unskilled positions averaging between $12.50 and $15 an hour.

Image removed.

During the two years the adult-use market could have been generating profits and creating jobs, Maine’s medical marijuana industry is likely to have taken a hit, however, losing 12 percent of its sales and about 69 jobs, according to Whitney’s estimates. Overall, however, that would still be a win in terms of dollars.

But faster does not always mean better, especially when it comes to marijuana, said Scott Gagnon, head of AdCare Educational Institute of Maine, director of the New England Prevention Technology Transfer Center and member of Maine’s soon-to-convene Marijuana Advisory Commission.

“Never a bad thing to not be in a rush to add a new commercial industry that sells addictive substances,” Gagnon said. “Rush to commercialization hurt states like Colorado and Washington, as it led to issues with youth use, impaired driving and youth access to potent marijuana edibles.”

He would have liked to see the advisory commission begin to meet sooner – it was created in 2018 when state lawmakers overrode Gov. Paul LePage’s legalization veto, but is meeting for the first time just this week – but is hopeful it still has the time to take steps to mitigate these public health issues.

“Now that the industry will be coming on line, I hope we will have robust and productive conversations to ensure we do everything we can to protect our youth and communities,” Gagnon said. “This must take priority over issues of profits and revenues.”

People disagree on the desirability of the delay, but most agree on the reason: former Gov. LePage.

“Maine has really been a bummer, and that bummer has a name: Paul LePage,” said Nic Easley, the CEO of 3C, a national marijuana consulting firm with clients in Maine. “You could have been the first in New England to legalize, but LePage handed all that money, all those jobs to Massachusetts.”

Easley said he knew several entrepreneurs who had considered Maine for business partnerships and investments and opted instead for Massachusetts, a larger state that legalized at the same time as Maine but went live in 2018. Some may return to Maine when sales start, but some are gone for good, he said.

“Who knows exactly what LePage cost you?” Easley said.

RELUCTANCE IN AUGUSTA

LePage was a staunch opponent of adult-use marijuana sales. He campaigned against the referendum question, then vetoed two post-legalization bills. Even after legislators overrode his veto, his administration did nothing to begin the process of writing regulations or licensing the industry.

LePage could not be reached for comment and didn’t respond to attempts to reach him through a former spokeswoman who now works at his public policy group and a former senior political adviser who is now a Washington, D.C.-based Republican political strategist.

There’s more to it than LePage, of course. The referendum in Maine had the smallest margin of victory – 51 to 49 percent – of any state that legalized adult-use sales. And Mainers who want marijuana can get it, either from the robust medical market or a long-lived black market, so there’s been no real public outcry.

Even Maine’s cannabis community was divided over legalization – many medical marijuana growers and patients worried it would spell the end of their market – so politicians didn’t feel overwhelming pressure to deliver on a question that lacked unanimous support among marijuana consumers.

Other states that legalized marijuana with governors who opposed it at the time managed to enact adult-use sales in spite of it, with the likes of Massachusetts’ Charlie Baker and Colorado’s John Hickenlooper eventually turning the people’s will into a reality.

Although LePage never publicly said “not under my watch,” he vowed not to move ahead with adult-use sales until Maine was ready, while doing very little to make that happen. Even after lawmakers overrode his veto, LePage hired no consultants, wrote no regulations, made no staff hires.

“The difference in Maine was you had a governor who just didn’t want to do it,” said Andrew Freedman, Colorado’s former marijuana czar who is now a consultant who has advised Maine on its adult-use rules. “If you’re a governor, you can just kick the can down the road if you want. That’s what he did.”

Matt Simon, the New England political director of the Marijuana Policy Project, said it is only natural to compare Maine and Massachusetts, two New England states that legalized cannabis on the same day. It took Masssachusetts 742 days to log its first adult-use sale, the country’s second-longest launch.

“The rollout in Massachusetts has been frustratingly slow in comparison with most of the West Coast states, but the process has certainly gone much more smoothly and quickly than in Maine,” he said. “It all comes back to Maine having a governor who persistently refused to accept the will of the people.”

According to Greg Huffaker, the director of client services at Canna Advisors who has advised marijuana clients in 40 states and countries, LePage’s anti-marijuana position outdid even former Florida Gov. Rick Scott, who tried every trick in the book to block expansion of that state’s medical cannabis program.

“Some states launch their marijuana programs at the direction of their voters and fix the problems when they come up,” Huffaker said. “Other states, like Maine and Florida, have executives in office that cite all the problems that could happen and say they want to fix them, when what they really want to do is stall.”

PLAYING CATCH-UP

That changed when LePage left office. His successor, Janet Mills, created the Office of Marijuana Policy in the Department of Administrative and Financial Services in February, just one month into her tenure, and began hiring consultants even before they had staffed the office.

The occupants of the new office don’t refer to LePage by name, but talk in terms of before and after a lot.

“I think there’s two different stories,” said Erik Gundersen, the marijuana office’s new director. “I think the ‘what’s taking so long’ is a history before the Office of Marijuana Policy. … Some work had been done, but we ended up having to backtrack on it.”

Under that scenario, Maine would roll out in just seven months, making it the fastest in the country.

Gundersen is proud of how much his office has accomplished in such a short time, and how closely it has worked with both other state agencies and the industry to develop sound state policies and regulations in record time. He hopes that brisk pace will allay any clock-watcher’s concerns.

“We understand people have been waiting a long time and there are a lot of money and small businesses that are waiting for this industry to roll out,” he said. “But at the same time, we have to make sure we do it right because we are still talking about an industry based around a federally illegal drug.”

Study suggests legal cannabis could create over 100,000 jobs in Florida

Florida voters may have the opportunity to legalize recreational marijuana at the ballot box next year, and a new study may help bolster the advocates’ case. 

The study, conducted by New Frontier Data, a Washington, D.C.-based think tank dedicated to providing empirical research on cannabis, suggests that the state could see a significant uptick in jobs over the next several years if pot is legalized. 

John Kagia, chief knowledge officer of New Frontier Data, said that if prohibition is lifted, the number of jobs in Florida related to hemp and pot could swell to 128,587 by 2025—a sevenfold increase from the nearly 17,000 cannabis jobs in the state.

Kagia, as quoted by the Miami New Times, that the types of jobs generated by the cannabis industry vary widely, including “lower-skilled labor roles such as trimmers or budtenders, [plus] higher-skilled workers like extraction tech, chemists, and other manufacturers dealing with edibles.”

The study also said that the Sunshine State could claim a 12 percent share of the entire nationwide cannabis market by 2025, which is expected to total almost $30 billion. 

Marijuana In The Sunshine State

Florida voters overwhelmingly approved a measure in 2016 that legalized medical marijuana, but a year later, the state’s Republican governor at the time, Rick Scott, signed a law prohibiting the smoking of cannabis in all forms. That changed earlier this year, when the state’s current governor, Ron DeSantis, also a Republican, signed a law overturning the ban.

“Over 70 percent of Florida voters approved medical marijuana in 2016,” DeSantis said in a statement after signing the law in March. “I thank my colleagues in the Legislature for working with me to ensure the will of the voters is upheld. Now that we have honored our duty to find a legislative solution, I have honored my commitment and filed a joint motion to dismiss the state’s appeal and to vacate the lower court decision which had held the prior law to be unconstitutional.”

Now, there’s a movement afoot to give voters the chance to go a step further and lift the prohibition on recreational use. Two separate groups of advocates are currently circulating petitions to propose a pair of similar questions on the Florida ballot next year. While both proposals would permit any Florida adult 21 or older to possess marijuana and consume it in private, only one would also permit Floridians to also grow cannabis at home.

Illicit cannabis companies find struggles, success in going legit

For many New York cannabis businesses operating in the illicit or gray market, preparing to go mainstream is essential. Some have made the move and are ready to share their wisdom. For those who haven’t, preparing during the lead up to the state’s eventual adult-use legalization could prove critical to securing a place in the one-day legal market. 

However, making the transition has its series of difficulties. 

New York State currently allows a select few options for cannabis business licenses. Ancillary businesses that don’t directly touch the plant are popular due to their ability to replicate virtually any other market without risk of violating the law. As such, these ventures often require little to no additional licensing, acting as any other legal business would. 

Companies like head shops and manufacturers are also seeing opportunity to a lesser degree. When it comes to the plant itself, though, the closest most companies can currently come to touching it is CBD. Under regulations, CBD cultivators and retailers can sell products, provided that they contain less than .3% THC. 

The only businesses allowed to touch THC-rich plants are the few vertically-integrated license holders granted by the state. New York officials began its program granting five licenses to companies, giving them the opportunity to open four dispensaries and one manufacturing location across New York. 

As program interest grew, parts of the state further suffered from lack of access to a dispensary. The state granted five additional licenses under the same four-dispensary, one manufacturing location arrangement to meet the demand. 

A limit on licenses is just one hurdle. The history of high entry costs have been a constant concern as well.

Estimates suggest that the price of entry for vertically-integrated licenses were between $15 and $30 million, according to various sources. The high price point to enter the space, if it were to open again any time, includes various fees and start-up costs. According to the state Department of Health, fees include a non-refundable $10,000 application, a $200,000 refundable payment to the state and the ability to prove a company can open the five mentioned locations. 

With limited access and a significant financial hurdle to clear, many deemed the venture impossible. Under adult-use legalization, however, access could expand greatly. 

Governor Andrew Cuomo’s so far failed adult-use legalization bill came at the expense of many promising outcomes. Criminal justice reform took the spotlight, and deservedly so. The shortcoming to pass the bill and overhaul a broken justice system, which includes scores of non-violent cannabis offenders, sparked the state to pass decriminalization measures as a momentary plan B for New Yorkers. 

If passed, the Governor’s Marihuana Regulation and Taxation Act would further address criminal justice efforts in the state, emphasizing penal justice and criminal procedure reform. 

Under the bill, entrepreneurs would also see expanded opportunities. The proposed Cuomo bill calls for licenses allowing cultivation, processing, distribution and sales of cannabis to people 21 or older. Licenses would expand to resemble those of other legalized adult-use markets. 

A plethora of business opportunities eventually will exist for companies, such as cannabis transportation, co-operatives, processing and just about every other venture imaginable. One area not likely to have been included in the bill was social consumption, an ongoing topic of discussion in cannabis as of late. 

Some entrepreneurs have already been able to pivot their illicit efforts into the mainstream. Often, this includes growers and cultivators. Adrian Edwards is the founder of Life Gardening Tools, a CBD venture that also focuses on urban gardening and bee advocacy. The company supports ethical beekeeping in Brooklyn, Staten Island and New Jersey in addition to selling an array of products from CBD oil, edibles, accessories and pre-rolled options it calls Hempette’s. 

The now legal CBD grower, extractor and retailer has over a decade of experience in the grey/white market. Most of his time has been in the illicit market, despite always seeking to enter the legal side of the market. 

Edwards, a black man, said he spent much of his time in the illicit market, often referred to as the black market, positing the inherent inequality of the growing legal, or white, market. To date, the industry continues to be largely caucasian-owned after decades of disproportionate policing during the drug war. Such policing continues to be an issue across the country. 

In the summer of 2018, Edwards saw a white-owned hemp store in the city. The revelation inspired him to go legal himself. “I realized if I didn’t get in now, then there was going to nothing but white-owned hemp and THC dispensaries while black people are still arrested and affected by the selective war on drugs,” Edwards explained.

When he wanted to make the transition, he did so with insights from leaders in the community, like Rep. Tremaine Wright, the representative for New York State Assembly District 56, representing the Bedford-Stuyvesant district of Brooklyn. 

Edwards attended a cannabis 101 event Rep. Wright hosted, which educated the community about CBD and its products. Rep. Wright passed on worthwhile advice to Edwards. “She told me to focus on advocacy and education in order to empower the folks who have been barred from benefiting from the cannabis industry,” said Edwards. 

He added, “Local politicians are doing their best to protect and heal their communities from the war on drugs.”

Edwards also credits Gia Morón, Executive Vice President of Women Grow, for teaching him “the importance of long-term thinking, patience, education and being an advocate.” He said Women Grow welcomed him with open arms, allowing him to be a representative for the black male community in the space. 

Going legal led Edwards to spend his time growing numerous revenue streams, including exclusive events and in-store sales. He also had to step out of his community to advance his network and funding. 

“When I first started, people in the African American community really didn’t know or care about hemp CBD. So, initially, I had to go to areas with the people who knew about CBD and had the money to pay for it.” He credits efforts like Rep. Wright’s for bridging this gap.

A year later, Edwards is fully mainstream and licensed. He considers the money, time and effort all worth it. He continues to network and market Life Gardening Tools today, and believes he has a business that can easily translate to an adult-use market if and when New York should legalize. 

He recommends others in the illicit market do the same. 

Transitioning from an illicit venture to a fully licensed one varies for businesses. Avis Bulbulyan is CEO of SIVA, a nationally cannabis consulting firm. Bulbulyan has over 12 years of experience in various cannabis sectors, including the Los Angeles’ Cannabis Task Force . He explained how market, sector, available resources and their commitment to the bigger picture all play a part. He noted a company should expect downtime during the transition. The cease in operation causes a loss in revenue. The downtime can last anywhere from a month to a year. 

“Most illicit operators can’t survive this part of the transition because of a lack of planning, short-sightedness in giving up immediate untaxed revenues for long-term growth and success,” he noted. 

He noted that New York’s current market is even more difficult due to the restriction on available licenses. “If you’re an operator in New York planning to stay in the industry, your best bet is to probably relocate to a different state.”

Bulbulyan agreed the financial hurdle is an issue, but is not the only one causing problems for possible entrepreneurs. He elaborated on what he considers a larger issue under current regulations, licensing. 

“What makes the state difficult is the nature of the licensing process, and the approach regulators take. New York has an extremely restrictive program with limited licenses issued. Being the best grower in the state would have nothing to do with securing a license.”

With scores of hurdles affecting New York and other illicit American cannabis ventures, it is unknown how many will successfully transition as the new cannabis normal sets in across the country. Hopefully, their hard work and sweat equity won’t be lost in the change.